Description: Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Home Page: www.inviongroup.com
100 Albert Road
Melbourne,
VIC
3205
Australia
Phone:
61 3 9692 7222
Officers
| Name | Title |
|---|---|
| Mr. Thian Chew | Executive Chairman & CEO |
| Ms. Melanie Jaye Leydin B.Bus, C.A. | CFO, Company Secretary & Non-Executive Director |
| Dr. Dean Naylor | Head of Intellectual Property Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3984 |
| Price-to-Sales TTM: | 3.5278 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |